TGRX-678 for CML that hasn't responded to other treatments
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new daily pill called TGRX-678 for people with chronic-phase CML who have not responded well to or cannot tolerate other CML treatments. It aims to see if the drug is safe and if it can help control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have chronic-phase chronic myeloid leukemia (CML-CP) that has not responded to or you cannot tolerate at least one TKI treatment.
- You are able to care for yourself (ECOG score 0-2).
- Your blood counts (absolute neutrophil count, hemoglobin, platelets) and kidney/liver function are adequate.
- You have not had active cancer treatment or other investigational drugs within the past 14 days.
- You are not pregnant, breastfeeding, and you agree to use highly effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication for people with chronic myeloid leukemia (CML) who have already tried at least three other treatments without success or with side effects. The goal is to see if this new drug can help control the leukemia.
This study tests an experimental pill (TQB3911) for people with chronic myeloid leukemia (CML) who have not responded well to or could not tolerate standard treatments. The goal is to find out if the drug is safe and what side effects it may cause.
This trial tests a new combination treatment for people with chronic myeloid leukemia (CML) whose disease is resistant to or intolerant of current standard drugs. The goal is to see if the study drug works better when combined with another drug, and to check its safety.
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
This trial tests a new pill combination for chronic lymphocytic leukemia (CLL) that has not been treated before. The drugs are designed to attack CLL cells in two different ways to try to improve outcomes.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
Hear when a new Chronic Myelogenous Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.